following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
We applied four, five or six cycles of moderately high doses of doxorubicin and cyclophosphamide supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). (coek.info)
Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
Radiotherapy2
Adjuvant chemotherapy is given after your initial treatment, such as surgery or radiotherapy. (owise.uk)
The standard of care therapy for GBM consists in surgical resection of the tumor, followed by radiotherapy and adjuvant plus concomitant chemotherapy with Temozolomide (TMZ) (Stupp protocol) ( 3 ). (frontiersin.org)
Neoadjuvant4
2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
Treatment protocols for bladder cancer are provided below, including those for chemotherapy, immunotherapy, and systemic neoadjuvant and adjuvant therapy. (medscape.com)
Secondly, we applied six cycles (when possible) of neoadjuvant chemotherapy instead of the more commonly used three cycles of chemotherapy followed by local therapy and three additional cycles of adjuvant chemotherapy [4]. (coek.info)
Neoadjuvant therapy may be recommended to people with HER2-positive, triple negative, breast cancer (BRCA) gene-positive, high risk or inflammatory breast cancer. (owise.uk)
Trastuzumab6
Neratinib: A tyrosine kinase inhibitor approved for the extended adjuvant treatment of patients with early-stage Her2Neu-positive breast cancer, following adjuvant trastuzumab-based therapy. (medscape.com)
The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens. (rxlist.com)
HERZUMA (trastuzumab-pkrb) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2 . (rxlist.com)
Each multiple-dose vial of HERZUMA delivers 420 mg trastuzumab-pkrb, 839 mg α,α-trehalose dihydrate, 9.5 mg L-histidine HCl, 6.1 mg L-histidine, and 1.7 mg polysorbate 20. (rxlist.com)
The bacteriostatic water for injection is a colourless, transparent solution, free of visible particles and is intended to use for the reconstitution of [BT-ON014 trade name] to yield a multi-dose solution containing 21 mg/mL trastuzumab at a pH of approximately 6.0. (who.int)
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. (gbg.de)
Leucovorin1
A new trial with UFT/leucovorin/epirubicin is ongoing. (cancernetwork.com)
Postoperative2
During the past decade perioperative chemotherapy, pre- or postoperative radio-chemotherapy, and, in Asian populations, adjuvant chemotherapy have been shown to improve the outcome of patients with advanced GC and GEJ cancers suited for surgery. (docksci.com)
In order to achieve a more effec- were recommended postoperative radiation and adjuvant tive and individualised chemotherapeutic treatment of breast chemotherapy. (lu.se)
Systemic1
In the U.S., KEYTRUDA plus LENVIMA is approved for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation and for adult patients with advanced renal cell carcinoma (RCC) in the first-line setting. (eisai.com)
Node-positive1
The CDK4/6 inhibitor abemaciclib (Verzenio) has been approved for use in hormone receptor (HR)-positive, Her2Neu-negative early breast cancer, for patients who have high-risk, node-positive disease and whose tumors have a Ki-67 score of ≥20%, as determined by a US Food and Drug Administration (FDA)-approved test. (medscape.com)
Postoperatively2
Periosteal lesions are one exception where adjuvant chemotherapy may be indicated postoperatively. (medscape.com)
three to four cycles of chemotherapy are given postoperatively (adjuvant). (medscape.com)
This regimen resulted in a 39% response rate and high toxicity. (cancernetwork.com)
A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin and represents the most common acute dose-limiting toxicity of this drug. (recallguide.org)
Early cardiac toxicity of epirubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes, but tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. (recallguide.org)
This toxicity appears to be dependent on the cumulative dose of Epirubicin Hydrochloride Injection and represents the cumulative dose-limiting toxicity of the drug. (recallguide.org)
Combination chemotherapy regimens are standard recommendations in the adjuvant setting. (medscape.com)
Therapy5
Adjuvant therapy for breast cancer is designed to treat any potential micrometastatic disease, or breast cancer cells that have escaped the breast and regional lymph nodes but have not yet established an identifiable metastasis. (medscape.com)
One week after the last weekly dose of Herzuma, administer 6 mg/kg as an IV infusion over 30-90 minutes every three weeks to complete a total of 52 weeks of therapy. (rxlist.com)
Epirubicin Hydrochloride Injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. (recallguide.org)
Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with Epirubicin Hydrochloride Injection. (recallguide.org)
If it occurs, delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin Hydrochloride Injection or within 2 to 3 months after completion of treatment, but later events (several months to years after treatment termination) have been reported. (recallguide.org)
Cycles1
A high response rate of 98% was observed, and patients who received six cycles of treatment showed an improvement in disease-free survival (DFS) and OS [1]. (coek.info)
Injection1
In a retrospective survey, including 9144 patients, mostly with solid tumors in advanced stages, the probability of developing CHF increased with increasing cumulative doses of Epirubicin Hydrochloride Injection (Figure 5). (recallguide.org)
Docetaxel1
The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
Clinical outcome2
Those values do not correlate with disease extent, although a very high LDH level is associated with a poor clinical outcome. (medscape.com)
Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
Survival3
In a univariate survival analysis with a median follow-up of 64 months, relatively high percentages of S100+ DC ( 8%) were associated with a longer disease-free survival (DFS) (P=0.078). (coek.info)
In patients with a high tumour load, where immunosuppressed conditions generally prevail, long-term administration of GM-CSF may thus contribute to survival through enhanced DC activation and consequently improved chances of effective antitumour immunity. (coek.info)
An increase in the total dose of chemotherapy seemed unlikely since other studies with dose-intensive chemotherapy failed to significantly improve survival [2,3]. (coek.info)
Toxicities1
Before beginning treatment with epirubicin, patients should recover from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment. (recallguide.org)
Breast2
Breast cancer has an extremely high incidence in women, and its morbidity and mortality rank first among female tumors. (encyclopedia.pub)
Breast cancer is currently a cancer with an extremely high incidence in women, and its mortality rank first among female tumors [ 1 ] . (encyclopedia.pub)
Tumors1
Success of conventional chemotherapeutic regiment is based on the principle that tumors with high growth fractions (such as acute myelogenous leukemia and the lymphomas, including Hodgkin's disease) are more sensitive to chemotherapy because a larger proportion of the targeted cells are undergoing cell division at any given time. (justia.com)
Indication1
These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not considered an indication for the suspension of epirubicin treatment. (recallguide.org)
Patients4
Cohort K enrolled 79 patients with MSI-H endometrial carcinoma and Cohort D enrolled 11 patients with MSI-H endometrial carcinoma for a total of 90 pooled patients who received KEYTRUDA as monotherapy (200 mg fixed dose every three weeks). (businesswire.com)
Following cancer treatment in many patients the risk of cardiovascular death may be higher than the actual risk of tumor recurrence. (leacurinaturiste.ro)
A significantly higher mean percentage of S100+ DC in the TDLN of the GM-CSF-treated patients (9.9%) was found compared with each of the respective control groups (5.3 and 5.1%, P=0.002). (coek.info)
Patients and methods proportion of the patients will recur despite treatment with adjuvant polychemotherapy. (lu.se)
Severe1
Nausea and vomiting may be less severe if doses are taken on an empty stomach at bedtime. (worthingtoncaron.com)
Agents1
Additionally, GBM is characterized by high inter-tumor and intra-tumor heterogeneity at a cellular, molecular, histological, and clinical level leading to very different responses to therapeutic agents and failure of targeted therapies ( 9 , 10 ). (frontiersin.org)
Additional1
This is attributed to the high association of Helicobacter pylori infection and additional nutritional and socioeconomic risk factors with distal GC in less-developed countries [54]. (docksci.com)
Tumor1
At the same time, a subpopulation of highly tumorigenic glioma stem cells (GSCs) with high plasticity and self-renewal properties contribute to tumor malignancy through their sustained proliferation, invasion, stimulation of angiogenesis, suppression of anti-tumor immune responses and chemo-resistance ( 12 ). (frontiersin.org)
Solution1
If HERZUMA is reconstituted with SWFI without preservative, the reconstituted solution is considered single-dose. (rxlist.com)